Abeona Therapeutics (ABEO) director sells 6,500 shares in open-market trade

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Abeona Therapeutics director Mark Alvino reported an open-market sale of company stock. He sold 6,500 shares of common stock on May 22, 2026 at a weighted average price of $5.4558 per share, through multiple trades priced between $5.44 and $5.47.

After this transaction, Alvino directly holds 77,565 shares of Abeona Therapeutics common stock. The filing notes that full details of the individual trade prices within the reported range are available upon request.

Insider Trade Summary

Net Seller: 6,500 shares ($35,463)

Net Sell 1 txn

Insider Alvino Mark

Role null

Sold 6,500 shs ($35K)

Type	Security	Shares	Price	Value
Sale	Common Stock	6,500	$5.4558	$35K

Holdings After Transaction: Common Stock — 77,565 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Shares sold: 6,500 shares Weighted average sale price: $5.4558 per share Post-transaction holdings: 77,565 shares +1 more

4 metrics

Shares sold 6,500 shares Open-market sale on May 22, 2026

Weighted average sale price $5.4558 per share Common stock sale on May 22, 2026

Post-transaction holdings 77,565 shares Shares directly owned after sale

Sale price range $5.44–$5.47 per share Range of individual trade prices

Key Terms

weighted average price, open-market sale, Form 4, non-derivative

4 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

non-derivative financial

""transaction_type": "non-derivative""

Form 4 Insider Transactions: What Each Field Means →

05/22/2026 - 05:24 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Alvino Mark

(Last)

(First)

(Middle)

6555 CARNEGIE AVE., 4TH FLOOR

(Street)

CLEVELAND

OHIO

44103

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/22/2026		S		6,500	D	$5.4558⁽¹⁾	77,565	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.44 to $5.47 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

	/s/ Mark Alvino	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Abeona Therapeutics (ABEO) report?

Abeona Therapeutics reported that director Mark Alvino sold 6,500 shares of common stock. The sale was an open-market transaction at a weighted average price of $5.4558 per share, executed across multiple trades within a narrow price range.

At what price did Mark Alvino sell Abeona Therapeutics (ABEO) shares?

Mark Alvino sold Abeona Therapeutics shares at a weighted average price of $5.4558. According to the filing, the individual trades occurred at prices ranging from $5.44 to $5.47 per share, reflecting a tightly clustered set of sale prices.

How many Abeona Therapeutics (ABEO) shares does Mark Alvino hold after the sale?

After the reported sale, Mark Alvino directly holds 77,565 shares of Abeona Therapeutics common stock. This post-transaction holding figure comes directly from the Form 4 and reflects his remaining direct ownership following the 6,500-share open-market sale.

Was the Abeona Therapeutics (ABEO) insider sale a single trade or multiple trades?

The insider sale was executed in multiple trades, not a single transaction. The Form 4 states the reported price is a weighted average, with individual trades occurring between $5.44 and $5.47 per share, and full trade-by-trade information available upon request.

What does a weighted average sale price mean in the Abeona Therapeutics (ABEO) Form 4?

The weighted average sale price of $5.4558 reflects several trades combined into one reported figure. Each trade occurred between $5.44 and $5.47 per share, and the average is calculated based on the number of shares sold at each individual price.